Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N.

J Clin Invest. 2013 Jan 2;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10.

PMID:
23221341
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS.

Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.

PMID:
21451123
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan 2;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10.

PMID:
23221337
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.

Dodd RD, Mito JK, Eward WC, Chitalia R, Sachdeva M, Ma Y, Barretina J, Dodd L, Kirsch DG.

Mol Cancer Ther. 2013 Sep;12(9):1906-17. doi: 10.1158/1535-7163.MCT-13-0189. Epub 2013 Jul 15.

PMID:
23858101
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
[PubMed - indexed for MEDLINE]
6.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

PMID:
22811580
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

PMID:
21057530
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.

Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A.

Int J Cancer. 2010 Jan 15;126(2):563-71. doi: 10.1002/ijc.24783.

PMID:
19634141
[PubMed - indexed for MEDLINE]
9.

PTEN dosage is essential for neurofibroma development and malignant transformation.

Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19479-84. doi: 10.1073/pnas.0910398106. Epub 2009 Oct 21.

PMID:
19846776
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.

Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.

Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518.

PMID:
18413802
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.

Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24.

PMID:
23292448
[PubMed - indexed for MEDLINE]
12.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

PMID:
20668238
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS.

Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26.

PMID:
23804705
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.

Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y.

Clin Cancer Res. 2006 Sep 15;12(18):5533-42.

PMID:
17000690
[PubMed - indexed for MEDLINE]
15.

Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cells.

Li H, Zhang X, Fishbein L, Kweh F, Campbell-Thompson M, Perrin GQ, Muir D, Wallace M.

Cancer Biol Ther. 2010 Oct 15;10(8):758-64. Epub 2010 Oct 15.

PMID:
20699653
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

PMID:
18381570
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis.

Woodruff JM.

Am J Med Genet. 1999 Mar 26;89(1):23-30. Review.

PMID:
10469433
[PubMed - indexed for MEDLINE]
18.

Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.

Clin Cancer Res. 2013 Jan 15;19(2):450-61. doi: 10.1158/1078-0432.CCR-12-1067. Epub 2012 Dec 3.

PMID:
23209032
[PubMed - indexed for MEDLINE]
Free Article
19.

Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system.

Brossier NM, Carroll SL.

Brain Res Bull. 2012 May 1;88(1):58-71. doi: 10.1016/j.brainresbull.2011.08.005. Epub 2011 Aug 10. Review.

PMID:
21855613
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro.

Ingram DA, Hiatt K, King AJ, Fisher L, Shivakumar R, Derstine C, Wenning MJ, Diaz B, Travers JB, Hood A, Marshall M, Williams DA, Clapp DW.

J Exp Med. 2001 Jul 2;194(1):57-69.

PMID:
11435472
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk